NHS National Pharmaceuticals Transition 2022_1
Potential periods of call-offs under the framework agreement:
Transition:
CESW: 29/07/2022 to 30/09/2023 (14 months)
LSNE: 29/07/2022 to 31/05/2024 (22 months)
NWLN: 29/07/2022 to 31/01/2023 (6 months)

Oral (plus non-parenteral) Products: All regions: 29/07/2022 to 31/05/2024 (22 months)

Hospital Only Products:
CESW: 29/07/2022 to 30/09/2023 (14 months)
LSNE: 29/07/2022 to 31/05/2024 (22 months)
NWLN: 29/07/2022 to 31/01/2023 (6 months)

Invitation to offer for NHS National Pharmaceuticals Transition 2022_1
Offer reference number: CM/PHG/21/5637/00
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.
Potential periods of call-offs under the framework agreement:
Transition: CESW: 29/07/2022 to 30/09/2023 (14 months)
LSNE: 29/07/2022 to 31/05/2024 (22 months)
NWLN: 29/07/2022 to 31/01/2023 (6 months)

Invitation to offer for NHS National Pharmaceuticals Transition 2022_1
Offer reference number: CM/PHG/21/5637/01
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.
Oral (plus non-parenteral) Products: All regions: 29/07/2022 to 31/05/2024 (22 months)

Invitation to offer for NHS National Pharmaceuticals Transition 2022_1
Offer reference number: CM/PHG/21/5637/02
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.
Hospital Only Products: CESW: 29/07/2022 to 30/09/2023 (14 months)
LSNE: 29/07/2022 to 31/05/2024 (22 months)
NWLN: 29/07/2022 to 31/01/2023 (6 months)